Insulin icodec
Once-weekly basal insulin — the biggest practical innovation in insulin since long-acting analogs reached the market.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
Novo Nordisk's once-weekly insulin. Approved in the EU in 2024; FDA issued a complete response letter in 2024 requesting additional data. The first weekly insulin to reach the market in any major jurisdiction.
- Class
- Once-weekly basal insulin analog
- Sponsor
- Novo Nordisk
- Stage
- Approved EU 2024; pending US (FDA CRL 2024)
- Lead use case
- Type 2 diabetes basal insulin therapy
What it is
Insulin icodec is a long-acting basal insulin engineered for once-weekly subcutaneous administration. The molecule binds reversibly to albumin in plasma, producing a stable circulating depot that releases insulin gradually across the dosing week.
Current research status
Approved in the EU as Awiqli in 2024 for type 2 diabetes. The FDA issued a complete response letter in 2024 requesting additional data, particularly around hypoglycemia risk in T1D, which has been the most discussed safety question. Approval in the US is pending resolution.
Mechanistic rationale
Insulin icodec is engineered with a fatty diacid side chain similar in concept to the half-life-extension strategy used for semaglutide. The reversible albumin binding produces sustained release with a half-life of approximately one week, supporting once-weekly subcutaneous dosing and a smoother glycemic profile than older basal insulins.
Available evidence
ONWARDS Phase 3 program (six trials) — Established non-inferiority or superiority versus once-daily basal insulins (degludec, glargine) for HbA1c reduction in type 2 diabetes.[1]
ONWARDS 6 (T1D) — In type 1 diabetes, insulin icodec showed higher rates of hypoglycemia than once-daily insulin, the finding that has driven the FDA's caution in approving for T1D contexts.
Why it's interesting
For patients on basal insulin therapy, the shift from daily to weekly injection is meaningful for adherence, lifestyle, and treatment-burden reasons. The 7-fold reduction in injection events over a year is the kind of practical change that meaningfully improves the experience of chronic disease management. For health systems, the impact on adherence is also substantial.
Limitations & risks
The hypoglycemia signal in T1D is the central safety question. The pharmacokinetic profile means dose adjustments take longer to manifest than with daily insulins — a missed dose, a sick day, or a major change in physical activity all interact with the weekly steady-state in ways that require careful clinical management. Patient education and clinical workflows around weekly insulin are still being established.
Community discussion notes
Significant interest in diabetes-specialty communities; less in biohacker / longevity discourse. The practical-impact framing — fewer injections, better adherence — is more medical than performance-oriented.
The takeaway
Insulin icodec is the first once-weekly insulin to reach a major market. Whether the FDA approves it for the US (and in which patient populations) will substantially shape global adoption. The molecule represents the most practical innovation in insulin therapy in roughly two decades.
References
- Rosenstock J, et al. Once-Weekly Insulin Icodec versus Once-Daily Insulin Glargine in T2D (ONWARDS 1). N Engl J Med. 2023;389(4):297-308. https://pubmed.ncbi.nlm.nih.gov/37356067/
- Russell-Jones D, et al. Once-Weekly Insulin Icodec versus Daily Insulin Degludec in T2D (ONWARDS 2). Lancet. 2023;402:1636-1647. https://pubmed.ncbi.nlm.nih.gov/?term=insulin+icodec+ONWARDS